CSI Market
Sign In | Register

Neogenomics Inc (NEO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NEO Annual Cash Flow →
The data below summarizes Neogenomics Inc's cash flow activity from Mar 31 2025 to Mar 31 2026, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-17.11
Depreciation & amortization8.78
Amortization of Other Assets7.63
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-1.27
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation9.64
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Capital Lease Obligations Incurred-
Operating Lease Expense1.72
Gain Loss On Termination Of Interest Rate Swap-
Equity Securities Fv Ni Unrealized Gain Loss-
Receivable With Imputed Interest Non Consolidated Affiliates-
Polymerase Chain Reaction Testing Exit Costs C O V I D-
Increase Decrease In Operating Lease Liability-1.30
Income taxes0.40
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-8.18
Increase (Decrease) in Accounts Payable and Other Operating Liabilities0.72
Increase (Decrease) in Accrued Liabilities-7.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets-2.16
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-8.14
Investing Activities
Capital Expenditures-5.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities0.00
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Business Combination Working Capital Adjustment-
Payments To Acquire Equity Securities Fv Ni-
Proceeds From Assets Held For Sale Net Of Closing Costs-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Payments to Fund Long-term Loans to Related Parties0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-5.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-0.34
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-159.62
Proceeds From Issuance Of Capital Lease On Owned Assets-
Repayments Of Equipment And Other Loans-
Proceeds From Equity Offering Net-
Repayments Of Equipment And Other Finance Obligation-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents159.62
Derivative Termination Fee-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.34
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-13.14
Total Cash Flow-13.48
4 historic quarters locked

Sign in to unlock the full Neogenomics Inc cash flow history.

Sign In Create Free Account

About Neogenomics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: July 28, 2026
  • Source: neo-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001077183-26-000059

Figures are derived from filed reports and may be restated. Historical data is subject to revision.